Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Disorders of Hemostasis

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.

Venous Thrombosis I: Introduction

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Pulmonary Embolism I: Introduction

Pulmonary Embolism I: Introduction

A blood clot, or thrombus, is a semi-solid mass composed of fibrin, platelets, and red blood cells. When it forms within a vessel, it can obstruct blood flow, known as thrombosis. If part of the clot detaches, it becomes an embolus that can travel and block distant vessels. When this occurs in the pulmonary arteries, it causes a condition known as pulmonary embolism (PE).Origin and ImpactMost often, the embolus originates from a thrombus in the deep veins of the lower limbs, a condition called...

Pulmonary Embolism I: Introduction

Pulmonary Embolism I: Introduction

Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Venetoclax with low-dose cytarabine, a forgotten combination in patients with acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review.

Hematology, transfusion and cell therapy·2024

Same author

Acute Myeloid Leukemia in Mexico: The Specific Challenges of a Developing Country. Results From a Multicenter National Registry.

Clinical lymphoma, myeloma & leukemia·2020

Same author

Survival analysis of adult patients with ALL in Mexico City: first report from the Acute Leukemia Workgroup (ALWG) (GTLA).

Cancer medicine·2018

Same author

Survival and treatment response in adults with acute promyelocytic leukemia treated with a modified International Consortium on Acute Promyelocytic Leukemia protocol.

Revista brasileira de hematologia e hemoterapia·2016

Same author

Outcomes of Substituting Oral Fludarabine for Intravenous Fludarabine in Combination with Cytarabine and Filgrastim for Treatment of Primary Refractory or Relapsed Acute Leukemias.

Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion·2015

Same author

Thalidomide and Dexamethasone Induction Therapy Until Best Response in Recently Diagnosed Patients with Multiple Myeloma: Results From a Pilot Study.

Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion·2015

Search research articles

Related Experiment Video

Updated: May 23, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Thrombosis and acute leukemia.

Erick Crespo-Solís¹

¹Clínica de Leucemia Aguda, Departamento de Hematología y Oncología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico. erickerickmx@yahoo.com.mx

Hematology (Amsterdam, Netherlands)

|April 18, 2012

Summary

This summary is machine-generated.

Thrombosis is a significant risk in acute leukemia patients, particularly adults. More research is needed on leukemia-specific factors, prevention, and treatment for acute lymphoid leukemia (ALL) and acute myeloid leukemia (AML).

More Related Videos

Venous Thrombosis Assay in a Mouse Model of Cancer

Venous Thrombosis Assay in a Mouse Model of Cancer

Published on: January 5, 2024

Related Experiment Videos

Last Updated: May 23, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Venous Thrombosis Assay in a Mouse Model of Cancer

Venous Thrombosis Assay in a Mouse Model of Cancer

Published on: January 5, 2024

Area of Science:

Hematology
Oncology
Vascular Medicine

Background:

Thrombosis is a frequent complication in acute leukemia patients.
Known risk factors in children include central venous lines, steroids, E. coli asparaginase, and hereditary thrombophilia.
Data on thrombosis in adult acute lymphoid leukemia (ALL) and acute myeloid leukemia (AML) patients is limited.

Purpose of the Study:

To highlight the scarcity of information on thrombosis pathogenesis, risk factors, and outcomes in adult ALL and AML.
To emphasize the need for expert consensus and guidelines on leukemia-specific thrombosis risk, prevention, and treatment.
To suggest that different acute leukemia subtypes may present unique thrombosis and bleeding risks.

Main Methods:

Literature review and expert opinion synthesis (implied).
Analysis of known risk factors and comparison between pediatric and adult populations.
Discussion of disease-specific pathogenic mechanisms and treatment considerations.

Main Results:

Thrombosis risk factors and outcomes in adult acute leukemia are not well-defined.
Chemotherapy protocols, patient health, co-existing risk factors, and disease biology likely influence thrombosis development.
Ethnicity and prevalence of hereditary risk factors may impact thrombosis risk, necessitating region-specific data.

Conclusions:

Expert consensus and guidelines are crucial for managing thrombosis in acute leukemia patients.
Each acute leukemia subtype may have distinct thrombosis and bleeding profiles.
Further research and reporting from diverse ethnic and geographic populations (Latin America, Asia, Africa) are essential.